# Fortress Biotech, Inc.: financial statements, quarterly

FBIO · Nasdaq · CIK 1429260 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fbio.md) · [Financials](/companies/fbio/financials.md) · [Filings](/companies/fbio/filings.md) · [Insiders](/companies/fbio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fbio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [34.8](/filings/0001558370-24-015740.md) | [19.9 d](/filings/0001558370-25-004160.md) | [13.0](/filings/0001558370-24-008299.md) | [14.9](/filings/0001558370-25-011570.md) | [14.6](/filings/0001104659-25-111989.md) | [15.1 d](/filings/0001104659-26-037874.md) | [13.1](/filings/0001104659-26-061233.md) | [16.4](/filings/0001104659-26-095964.md) | [17.6](/filings/0001104659-25-111989.md) | [16.1 d](/filings/0001104659-26-037874.md) | [16.0](/filings/0001104659-26-061233.md) | [18.7](/filings/0001104659-26-095964.md) |
| Cost of revenue | $m | [6.4](/filings/0001558370-24-015740.md) | [2.2 d](/filings/0001558370-25-004160.md) | [6.0](/filings/0001558370-25-007898.md) | [5.7](/filings/0001558370-25-011570.md) | [4.5](/filings/0001104659-25-111989.md) | [4.7 d](/filings/0001104659-26-037874.md) | [4.8](/filings/0001104659-26-061233.md) | [4.9](/filings/0001104659-26-095964.md) | [5.8](/filings/0001104659-25-111989.md) | [5.4 d](/filings/0001104659-26-037874.md) | [6.2](/filings/0001104659-26-061233.md) | [6.1](/filings/0001104659-26-095964.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [20.3](/filings/0001558370-24-015740.md) | [14.1 d](/filings/0001558370-24-004272.md) | [24.8](/filings/0001558370-24-008299.md) | [12.7](/filings/0001558370-24-012063.md) | [9.4](/filings/0001558370-24-015740.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [21.7](/filings/0001558370-24-015740.md) | [19.5 d](/filings/0001558370-25-004160.md) | [17.9](/filings/0001558370-25-007898.md) | [20.8](/filings/0001558370-25-011570.md) | [22.0](/filings/0001104659-25-111989.md) | [26.9 d](/filings/0001104659-26-037874.md) | [25.7](/filings/0001104659-26-061233.md) | [38.8](/filings/0001104659-26-095964.md) | [17.4](/filings/0001104659-25-111989.md) | [14.7 d](/filings/0001104659-26-037874.md) | [15.9](/filings/0001104659-26-061233.md) | [20.8](/filings/0001104659-26-095964.md) |
| Operating income | $m | [(13.8)](/filings/0001558370-24-015740.md) | [(19.6) d](/filings/0001558370-25-004160.md) | [(36.6)](/filings/0001558370-25-007898.md) | [(27.8)](/filings/0001558370-25-011570.md) | [(22.1)](/filings/0001104659-25-111989.md) | [(23.8) d](/filings/0001104659-26-037874.md) | [(22.3)](/filings/0001104659-26-061233.md) | [(36.5)](/filings/0001104659-26-095964.md) | [(6.8)](/filings/0001104659-25-111989.md) | [(4.8) d](/filings/0001104659-26-037874.md) | [(7.7)](/filings/0001104659-26-061233.md) | [(10.0)](/filings/0001104659-26-095964.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0001558370-24-015740.md) | [0.4 d](/filings/0001558370-25-004160.md) | [0.0](/filings/0001558370-25-007898.md) | [0.0](/filings/0001558370-25-011570.md) | [0.1](/filings/0001104659-25-111989.md) | [0.3 d](/filings/0001104659-26-037874.md) | [0.0](/filings/0001104659-26-061233.md) | [0.0](/filings/0001558370-25-011570.md) | [0.0](/filings/0001104659-25-111989.md) | [(0.8) d](/filings/0001104659-26-037874.md) | [5.1](/filings/0001104659-26-061233.md) | [0.3](/filings/0001104659-26-095964.md) |
| Net income | $m | [(5.0)](/filings/0001558370-24-015740.md) | [(9.3) d](/filings/0001558370-25-004160.md) | [(15.4)](/filings/0001558370-25-007898.md) | [(10.9)](/filings/0001558370-25-011570.md) | [(12.9)](/filings/0001104659-25-111989.md) | [(6.8) d](/filings/0001104659-26-037874.md) | [(10.6)](/filings/0001104659-26-061233.md) | [15.5](/filings/0001104659-26-095964.md) | [5.9](/filings/0001104659-25-111989.md) | [(3.9) d](/filings/0001104659-26-037874.md) | [110](/filings/0001104659-26-061233.md) | [(0.5)](/filings/0001104659-26-095964.md) |
| Diluted EPS | $ per share | [(0.94)](/filings/0001558370-24-015740.md) | not reported | [(1.04)](/filings/0001558370-25-007898.md) | [(0.73)](/filings/0001558370-25-011570.md) | [(0.76)](/filings/0001104659-25-111989.md) | not reported | [(0.48)](/filings/0001104659-26-061233.md) | [0.45](/filings/0001104659-26-095964.md) | [0.11](/filings/0001104659-25-111989.md) | not reported | [2.82](/filings/0001104659-26-061233.md) | [(0.08)](/filings/0001104659-26-095964.md) |
| Basic EPS | $ per share | [(0.94)](/filings/0001558370-24-015740.md) | not reported | [(1.04)](/filings/0001558370-25-007898.md) | [(0.73)](/filings/0001558370-25-011570.md) | [(0.76)](/filings/0001104659-25-111989.md) | not reported | [(0.48)](/filings/0001104659-26-061233.md) | [0.50](/filings/0001104659-26-095964.md) | [0.13](/filings/0001104659-25-111989.md) | not reported | [3.44](/filings/0001104659-26-061233.md) | [(0.08)](/filings/0001104659-26-095964.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [72.3](/filings/0001558370-24-015740.md) | [80.9](/filings/0001558370-25-004160.md) | [83.8](/filings/0001558370-25-007898.md) | [76.2](/filings/0001558370-25-011570.md) | [58.9](/filings/0001104659-25-111989.md) | [57.3](/filings/0001104659-26-037874.md) | [91.3](/filings/0001104659-26-061233.md) | [74.4](/filings/0001104659-26-095964.md) | [86.2](/filings/0001104659-25-111989.md) | [79.4](/filings/0001104659-26-095964.md) | [256](/filings/0001104659-26-061233.md) | [197](/filings/0001104659-26-095964.md) |
| Current assets | $m | [97.8](/filings/0001558370-23-019050.md) | [117](/filings/0001558370-25-004160.md) | [117](/filings/0001558370-24-008299.md) | [103](/filings/0001558370-24-012063.md) | [86.3](/filings/0001558370-24-015740.md) | [90.4](/filings/0001104659-26-037874.md) | [127](/filings/0001558370-25-007898.md) | [110](/filings/0001558370-25-011570.md) | [119](/filings/0001104659-25-111989.md) | [124](/filings/0001104659-26-095964.md) | [295](/filings/0001104659-26-061233.md) | [246](/filings/0001104659-26-095964.md) |
| Total assets | $m | [151](/filings/0001558370-23-019050.md) | [168](/filings/0001558370-25-004160.md) | [165](/filings/0001558370-25-007898.md) | [146](/filings/0001558370-25-011570.md) | [127](/filings/0001104659-25-111989.md) | [144](/filings/0001104659-26-037874.md) | [178](/filings/0001104659-26-061233.md) | [160](/filings/0001104659-26-095964.md) | [181](/filings/0001104659-25-111989.md) | [186](/filings/0001104659-26-095964.md) | [357](/filings/0001104659-26-061233.md) | [317](/filings/0001104659-26-095964.md) |
| Current liabilities | $m | [97.4](/filings/0001558370-23-019050.md) | [84.9](/filings/0001558370-25-004160.md) | [87.7](/filings/0001558370-24-008299.md) | [75.5](/filings/0001558370-24-012063.md) | [70.3](/filings/0001558370-24-015740.md) | [71.4](/filings/0001104659-26-037874.md) | [73.7](/filings/0001558370-25-007898.md) | [57.5](/filings/0001558370-25-011570.md) | [54.1](/filings/0001104659-25-111989.md) | [49.7](/filings/0001104659-26-095964.md) | [103](/filings/0001104659-26-061233.md) | [62.0](/filings/0001104659-26-095964.md) |
| Total liabilities | $m | [164](/filings/0001558370-23-019050.md) | [166](/filings/0001558370-25-004160.md) | [169](/filings/0001558370-24-008299.md) | [160](/filings/0001558370-24-012063.md) | [140](/filings/0001558370-24-015740.md) | [146](/filings/0001104659-26-037874.md) | [146](/filings/0001558370-25-007898.md) | [123](/filings/0001558370-25-011570.md) | [116](/filings/0001104659-25-111989.md) | [123](/filings/0001104659-26-095964.md) | [155](/filings/0001104659-26-061233.md) | [111](/filings/0001104659-26-095964.md) |
| Long-term debt | $m | [45.8](/filings/0001558370-23-019050.md) | [60.9](/filings/0001558370-25-004160.md) | [61.4](/filings/0001558370-24-008299.md) | [67.0](/filings/0001558370-24-012063.md) | [52.5](/filings/0001558370-24-015740.md) | [58.0](/filings/0001104659-26-037874.md) | [56.4](/filings/0001558370-25-007898.md) | [50.0](/filings/0001558370-25-011570.md) | [47.8](/filings/0001104659-25-111989.md) | [54.5](/filings/0001104659-26-095964.md) | [37.5](/filings/0001104659-26-061233.md) | [35.0](/filings/0001104659-26-095964.md) |
| Shareholders' equity | $m | [16.7](/filings/0001558370-23-019050.md) | [22.5](/filings/0001558370-25-004160.md) | [23.0](/filings/0001558370-24-008299.md) | [17.9](/filings/0001558370-24-012063.md) | [21.2](/filings/0001558370-24-015740.md) | [22.7](/filings/0001104659-26-037874.md) | [22.3](/filings/0001558370-25-007898.md) | [43.9](/filings/0001558370-25-011570.md) | [55.9](/filings/0001104659-25-111989.md) | [49.9](/filings/0001104659-26-095964.md) | [162](/filings/0001104659-26-061233.md) | [164](/filings/0001104659-26-095964.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.8) d](/filings/0001558370-24-015740.md) | [(34.9) d](/filings/0001558370-25-004160.md) | [(25.4)](/filings/0001558370-25-007898.md) | [(21.8) d](/filings/0001558370-25-011570.md) | [(20.1) d](/filings/0001104659-25-111989.md) | [(12.9) d](/filings/0001104659-26-037874.md) | [(19.6)](/filings/0001104659-26-061233.md) | [(27.6) d](/filings/0001104659-26-095964.md) | [(6.1) d](/filings/0001104659-25-111989.md) | [(12.5) d](/filings/0001104659-26-037874.md) | [204](/filings/0001104659-26-061233.md) | [(59.3) d](/filings/0001104659-26-095964.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-015740.md) | [0.0 d](/filings/0001558370-25-004160.md) | not reported | not reported | [0.0 d](/filings/0001558370-24-015740.md) | [0.0 d](/filings/0001558370-25-004160.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [0.2 d](/filings/0001558370-24-015740.md) | [0.2 d](/filings/0001558370-25-004160.md) | [0.2](/filings/0001558370-25-007898.md) | [0.2 d](/filings/0001558370-25-011570.md) | [0.2 d](/filings/0001104659-25-111989.md) | [0.2 d](/filings/0001104659-26-037874.md) | [0.2](/filings/0001104659-26-061233.md) | [0.2 d](/filings/0001104659-26-095964.md) | [0.2 d](/filings/0001104659-25-111989.md) | [0.2 d](/filings/0001104659-26-037874.md) | [0.0](/filings/0001104659-26-061233.md) | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.0](/filings/0001558370-23-019050.md) | [102](/filings/0001558370-23-009855.md) | [7.4](/filings/0001558370-24-012063.md) | [7.5](/filings/0001558370-24-015740.md) | [17.2](/filings/0001558370-25-007898.md) | [18.3](/filings/0001558370-25-011570.md) | [19.7](/filings/0001104659-25-111989.md) | [26.5](/filings/0001104659-26-061233.md) | [29.8](/filings/0001104659-26-095964.md) | [33.1](/filings/0001104659-25-111989.md) | [38.4](/filings/0001104659-26-061233.md) | [31.8](/filings/0001104659-26-095964.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 82,474,127 at 2020-05-07, from the cover of the [10-Q filed 2020-05-11](/filings/0001104659-20-059592.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.